DOCSLIB.ORG

A Mixed Modality Approach Towards Xi Reactivation for Rett Syndrome And

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Mixed Modality Approach Towards Xi Reactivation for Rett Syndrome And A mixed modality approach towards Xi reactivation for PNAS PLUS Rett syndrome and other X-linked disorders Lieselot L. G. Carrettea,b,c,d, Chen-Yu Wanga,b,c, Chunyao Weia,b,c, William Pressa,b,c, Weiyuan Mae,f, Raymond J. Kelleher IIIe,f, and Jeannie T. Leea,b,c,1 aHoward Hughes Medical Institute, Massachusetts General Hospital, Boston, MA 02114; bDepartment of Molecular Biology, Massachusetts General Hospital, Boston, MA 02114; cDepartment of Genetics, Harvard Medical School, Boston, MA 02115; dCenter for Medical Genetics, Ghent University, 9000 Ghent, Belgium; eCenter for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114; and fDepartment of Neurology, Massachusetts General Hospital, Boston, MA 02114 Contributed by Jeannie T. Lee, December 1, 2017 (sent for review August 28, 2017; reviewed by Ingolf Bach and Gyorgyi Csankovszki) The X-chromosome harbors hundreds of disease genes whose however, two obstacles to an Xi-reactivation strategy. First, sex associated diseases predominantly affect males. However, a sub- chromosomal dosage compensation is known to be important set, including neurodevelopmental disorders, Rett syndrome (RTT), throughout development and life: Perturbing XCI by a germline fragile X syndrome, and CDKL5 syndrome, also affects females. deletion of the master regulator Xist resulted in inviable female These disorders lack disease-specific treatment. Because female embryos (8), an epiblast-specific deletion of Xist caused severely cells carry two X chromosomes, an emerging treatment strategy reduced female fitness (9), and a conditional deletion of Xist in has been to reawaken the healthy allele on the inactive X (Xi). blood caused fully penetrant hematological cancers (10). Per- Here, we focus on methyl-CpG binding protein 2 (MECP2) resto- turbing dosage balance via Xi reactivation could therefore have ration for RTT and combinatorially target factors in the interac- untoward physiological consequences. On the other hand, loss of tome of Xist, the noncoding RNA responsible for X inactivation. Xist and partial reactivation occur naturally in lymphocytes (11), We identify a mixed modality approach combining an Xist antisense and may therefore be tolerated in vivo under controlled cir- oligonucleotide and a small-molecule inhibitor of DNA methylation, cumstances. A second challenge is that the Xi has been difficult which, together, achieve 30,000-fold MECP2 up-regulation from Xist to reactivate via pharmacological means due to multiple parallel GENETICS the Xi in cultured cells. Combining a brain-specific genetic – ablation with short-term 5-aza-2′-deoxycytidine (Aza) treatment mechanisms of epigenetic silencing (1 3, 12). Progress has been models the synergy in vivo without evident toxicity. The Xi is made in recent years, however. Several siRNA screens identified selectively reactivated. These experiments provide proof of con- several factors regulating Xi stability, but no overlap of candi- cept for a mixed modality approach for treating X-linked disorders dates was observed between them (13, 14), perhaps because the in females. screens were not saturating. Others have identified the TGF-β pathway (15), a synergism between Aurora kinase and DNA X reactivation | antisense oligonucleotides | LNA | Rett syndrome | Xist methylation in a primed small-molecule screen (16), as well as a iseases caused by a mutation on the mammalian X chro- Significance Dmosome affect males and females differently as males have only one X chromosome and females have two. Female X The X-chromosome harbors hundreds of disease genes, a sub- chromosomes are, however, subject to a dosage compensation set of which gives rise to neurodevelopmental disorders mechanism in which one X chromosome is inactivated. Because such as Rett syndrome (RTT), fragile X syndrome, and of “X-chromosome inactivation” (XCI), the female mammal is a CDKL5 syndrome. There is presently no disease-specific treat- mosaic of cells that expresses either the maternal or paternal X ment. Here, we work toward a therapeutic program based on chromosome (1–3). Thus, heterozygous X-linked mutations reactivation of the silent X chromosome to restore expression would affect approximately half of a female’s somatic cells. For of the missing protein. We develop a mixed modality approach gene products with a non–cell-autonomous function, healthy that combines a small-molecule inhibitor of DNA methylation cells can usually compensate for those expressing the mutation and an antisense oligonucleotide against Xist RNA. This com- (e.g., factor VIII for hemophilia). With mutations in gene bination achieves up to 30,000-fold methyl-CpG binding pro- products that fulfill a critical role within the cells that produce tein 2 upregulation in cultured cells. In vivo modeling using a Xist ′ them on the other hand, deficits in just half of the body’s somatic conditional knockout and 5-aza-2 -deoxycytidine recapit- cells can result in a severe disorder. One well-known example is ulates inactive X reactivation. These findings provide proof of Rett syndrome (RTT), a human neurodevelopmental disorder concept for the mixed modality approach to treat X-linked caused by a mutation in the methyl-CpG binding protein 2 disorders, including RTT. (MECP2) (4), a chromatin-associated gene product that is cru- Author contributions: L.L.G.C. and J.T.L. designed research; L.L.G.C. performed research; cial for neuronal development. Whereas males do not survive, W.P., W.M., and R.J.K. contributed new mouse lines/analytic tools; L.L.G.C. and J.T.L. females are typically born and remain symptom-free until the analyzed data; C.-Y. W. and C.W. performed bioinformatic analysis; and L.L.G.C. and first or second year of life. Then, symptoms arise that include J.T.L. wrote the paper. motor abnormalities, severe seizures, absent speech, and autism Reviewers: I.B., UMass Medical School; and G.C., University of Michigan. (5). To date, no disease-specific therapy is available for this Conflict of interest statement: J.T.L. is a founder and scientific advisory board member of disorder, which affects one in ∼10,000 girls throughout Translate Bio and Fulcrum Therapeutics. Patents have also been filed on the subject matter. the world. Published under the PNAS license. Notably, females carry a potential cure within their own cells. Data deposition: The data reported in this paper have been deposited in the Gene Ex- Every affected cell harbors a normal but dormant copy of pression Omnibus (GEO) database, https://www.ncbi.nlm.nih.gov/geo (accession no. MECP2 on the inactive X (Xi) chromosome, which may, in GSE97077). principle, be reactivated to alleviate disease burden. Intriguingly, 1To whom correspondence should be addressed. Email: [email protected]. in male RTT mouse models, restoring normal Mecp2 expression This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. can reverse disease after the onset of symptoms (6, 7). There are, 1073/pnas.1715124115/-/DCSupplemental. www.pnas.org/cgi/doi/10.1073/pnas.1715124115 PNAS Early Edition | 1of8 Downloaded by guest on September 29, 2021 synergism between a ribonucleotide reductase subunit (RRM2) A qB qD qF1 qE1 qC1 qA5 qA2 qA6 qE2 qE3 qF2 qF3 qF4 qA4 qF5 qC2 ′ qC3 and 5-aza-2 -deoxycytidine (17). In a more direct approach, an qA1.1 qA3.1 qA7.1 qA3.2 qA1.2 qA7.2 qA7.3 a Xist RNA proteomic screen identified more than 100 interacting X Xist proteins and demonstrated that de-repression of the Xi could be Mecp2 s p r l n achieved robustly only when two to three interactors were tar- L1cam Naa10 Irak1 Opn1mw Flna Dnase1l1 Plxna3 Ubl4 geted simultaneously (18). In all studies to date, MECP2 resto- k Avpr2 Hcfc1 Mecp2 Tktl1 Emd Gdi1 Lage3 << o m ration has been extremely limited ( 1% of normal levels). Here, q g we integrate the existing knowledge and explore new methods of hij d b Xi reactivation. We arrive at a mixed modality approach, in- e f c Mecp2 cluding an antisense oligonucleotide (ASO) against Xist and an inhibitor of DNA methylation, the combination of which achieves B 1.5 a 30,000-fold reactivation of MECP2 from the Xi. 1 0.5 Results 0.02 0.015 Pharmacological Synergy Through a Mixed Modality Approach. While 0.01 the pharmaceutical industry has focused almost exclusively on 0.005 0 i j l r f k s e g n o p q b d h c targeting proteins, long noncoding RNAs (lncRNAs) have be- m Aza come increasingly attractive as pharmacological targets (19). blank control Xist = a Xa active Improving ASO technology makes lncRNAs pharmacologically untreated relative luciferase counts / cell accessible. ASOs are high-molecular-weight compounds that reference Aza + ASO have been optimized over the past 50 y through chemical mod- ifications to acquire greater stability, selectivity, and bio- availability (20, 21). Since ASOs bind their target through C Function Protein Class Inhibitor DNA modification DNMT Aza (DNMT1) Watson–Crick base-pairing interactions, they can be rationally DNA topology TOP topotecan (TOP1), designed and hit previously “undruggable” targets. Notably, ASO etoposide (TOP2) DNA repair PARP olaparib technology has achieved success in treating hypercholesterolemia Histone modification Histone PRT4165 (RING1 of PRC1), (Kynamro) and spinal muscular atrophy (Spinraza). ubiquitination We asked whether an ASO could also be developed for Xi HMT EPZ6438 (EZH2 of PRC2), A366 (G9A) reactivation and screened a small ASO library against various AURK VX680 (AURK), barasertib (AURKB) targets of potential interest, including Xist RNA and an anti- HDAC vorinostat & vorinostat (HDAC), romidepsin (HDAC1&2), sense transcript to Mecp2 (Mecp2-as) (Fig. 1A, Fig. S1, and entinostat (HDAC1&3), Table S1). In designing the ASOs, we chose phosphorothioate rocilinostat & tubastatin a (HDAC6) backbone and locked nucleic acid (LNA) chemistry (22) for its in HAT SGC-CBP30 (CREBBP) Chromatin remodeling SWI/SNF PFI-3 (SMARCA4/BRG1) vivo and in vitro stability, and increased affinity and selectivity Epigenetic reader BET JQ1, I-BRD9 (BRD9) for RNA targets.
Load more

Recommended publications
  • Environmental Influences on Endothelial Gene Expression
    ENDOTHELIAL CELL GENE EXPRESSION John Matthew Jeff Herbert Supervisors: Prof. Roy Bicknell and Dr. Victoria Heath PhD thesis University of Birmingham August 2012 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. ABSTRACT Tumour angiogenesis is a vital process in the pathology of tumour development and metastasis. Targeting markers of tumour endothelium provide a means of targeted destruction of a tumours oxygen and nutrient supply via destruction of tumour vasculature, which in turn ultimately leads to beneficial consequences to patients. Although current anti -angiogenic and vascular targeting strategies help patients, more potently in combination with chemo therapy, there is still a need for more tumour endothelial marker discoveries as current treatments have cardiovascular and other side effects. For the first time, the analyses of in-vivo biotinylation of an embryonic system is performed to obtain putative vascular targets. Also for the first time, deep sequencing is applied to freshly isolated tumour and normal endothelial cells from lung, colon and bladder tissues for the identification of pan-vascular-targets. Integration of the proteomic, deep sequencing, public cDNA libraries and microarrays, delivers 5,892 putative vascular targets to the science community.
    [Show full text]
  • Ageing-Associated Changes in DNA Methylation in X and Y Chromosomes
    Kananen and Marttila Epigenetics & Chromatin (2021) 14:33 Epigenetics & Chromatin https://doi.org/10.1186/s13072-021-00407-6 RESEARCH Open Access Ageing-associated changes in DNA methylation in X and Y chromosomes Laura Kananen1,2,3,4* and Saara Marttila4,5* Abstract Background: Ageing displays clear sexual dimorphism, evident in both morbidity and mortality. Ageing is also asso- ciated with changes in DNA methylation, but very little focus has been on the sex chromosomes, potential biological contributors to the observed sexual dimorphism. Here, we sought to identify DNA methylation changes associated with ageing in the Y and X chromosomes, by utilizing datasets available in data repositories, comprising in total of 1240 males and 1191 females, aged 14–92 years. Results: In total, we identifed 46 age-associated CpG sites in the male Y, 1327 age-associated CpG sites in the male X, and 325 age-associated CpG sites in the female X. The X chromosomal age-associated CpGs showed signifcant overlap between females and males, with 122 CpGs identifed as age-associated in both sexes. Age-associated X chro- mosomal CpGs in both sexes were enriched in CpG islands and depleted from gene bodies and showed no strong trend towards hypermethylation nor hypomethylation. In contrast, the Y chromosomal age-associated CpGs were enriched in gene bodies, and showed a clear trend towards hypermethylation with age. Conclusions: Signifcant overlap in X chromosomal age-associated CpGs identifed in males and females and their shared features suggest that despite the uneven chromosomal dosage, diferences in ageing-associated DNA methylation changes in the X chromosome are unlikely to be a major contributor of sex dimorphism in ageing.
    [Show full text]
  • Molecular Effects of Isoflavone Supplementation Human Intervention Studies and Quantitative Models for Risk Assessment
    Molecular effects of isoflavone supplementation Human intervention studies and quantitative models for risk assessment Vera van der Velpen Thesis committee Promotors Prof. Dr Pieter van ‘t Veer Professor of Nutritional Epidemiology Wageningen University Prof. Dr Evert G. Schouten Emeritus Professor of Epidemiology and Prevention Wageningen University Co-promotors Dr Anouk Geelen Assistant professor, Division of Human Nutrition Wageningen University Dr Lydia A. Afman Assistant professor, Division of Human Nutrition Wageningen University Other members Prof. Dr Jaap Keijer, Wageningen University Dr Hubert P.J.M. Noteborn, Netherlands Food en Consumer Product Safety Authority Prof. Dr Yvonne T. van der Schouw, UMC Utrecht Dr Wendy L. Hall, King’s College London This research was conducted under the auspices of the Graduate School VLAG (Advanced studies in Food Technology, Agrobiotechnology, Nutrition and Health Sciences). Molecular effects of isoflavone supplementation Human intervention studies and quantitative models for risk assessment Vera van der Velpen Thesis submitted in fulfilment of the requirements for the degree of doctor at Wageningen University by the authority of the Rector Magnificus Prof. Dr M.J. Kropff, in the presence of the Thesis Committee appointed by the Academic Board to be defended in public on Friday 20 June 2014 at 13.30 p.m. in the Aula. Vera van der Velpen Molecular effects of isoflavone supplementation: Human intervention studies and quantitative models for risk assessment 154 pages PhD thesis, Wageningen University, Wageningen, NL (2014) With references, with summaries in Dutch and English ISBN: 978-94-6173-952-0 ABSTRact Background: Risk assessment can potentially be improved by closely linked experiments in the disciplines of epidemiology and toxicology.
    [Show full text]
  • Newfound Coding Potential of Transcripts Unveils Missing Members Of
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.02.406710; this version posted December 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 Newfound coding potential of transcripts unveils missing members of 2 human protein communities 3 4 Sebastien Leblanc1,2, Marie A Brunet1,2, Jean-François Jacques1,2, Amina M Lekehal1,2, Andréa 5 Duclos1, Alexia Tremblay1, Alexis Bruggeman-Gascon1, Sondos Samandi1,2, Mylène Brunelle1,2, 6 Alan A Cohen3, Michelle S Scott1, Xavier Roucou1,2,* 7 1Department of Biochemistry and Functional Genomics, Université de Sherbrooke, Sherbrooke, 8 Quebec, Canada. 9 2 PROTEO, Quebec Network for Research on Protein Function, Structure, and Engineering. 10 3Department of Family Medicine, Université de Sherbrooke, Sherbrooke, Quebec, Canada. 11 12 *Corresponding author: Tel. (819) 821-8000x72240; E-Mail: [email protected] 13 14 15 Running title: Alternative proteins in communities 16 17 Keywords: alternative proteins, protein network, protein-protein interactions, pseudogenes, 18 affinity purification-mass spectrometry 19 20 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.02.406710; this version posted December 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 21 Abstract 22 23 Recent proteogenomic approaches have led to the discovery that regions of the transcriptome 24 previously annotated as non-coding regions (i.e.
    [Show full text]
  • Profiling Estrogen-Regulated Gene Expression Changes in Normal And
    Oncogene (2005) 24, 8128–8143 & 2005 Nature Publishing Group All rights reserved 0950-9232/05 $30.00 www.nature.com/onc Profiling estrogen-regulated gene expression changes in normal and malignant human ovarian surface epithelial cells Viqar Syed1, Xiang Zhang1, Kin-Mang Lau1,4, Robert Cheng1, Kasturi Mukherjee1 and Shuk-Mei Ho*,1,2,3 1Department of Surgery, University of Massachusetts Medical School, Worcester, MA, USA; 2Department of Cell Biology, University of Massachusetts Medical School, Worcester, MA, USA; 3Department of Physiology, University of Massachusetts Medical School, Worcester, MA, USA Estrogens regulate normal ovarian surface epithelium been identified due to their differential responses to E2 (OSE) cell functions but also affect epithelial ovarian between the two cell types. These findings may explain the cancer (OCa) development. Little is known about how paradoxical roles of estrogens in regulating normal and estrogens play such opposing roles. Transcriptional malignant OSE cell functions. profiling using a cDNA microarray containing 2400 Oncogene (2005) 24, 8128–8143. doi:10.1038/sj.onc.1208959 named genes identified 155 genes whose expression was published online 22 August 2005 altered by estradiol-17b (E2) in three immortalized normal human ovarian surface epithelial (HOSE) cell Keywords: erythrocyte adducin a subunit clone; 5.1 lines and 315 genes whose expression was affected by the RNA-binding protein S1; nuclear protein SkiP; Rap-2; hormone in three established OCa (OVCA) cell lines. All plexin A3; Sex gene but 19 of the genes in these two sets were different. Among the 19 overlapping genes, five were found to show discordant responses between HOSE and OVCA cell lines.
    [Show full text]
  • Nature Cell Biology | VOL 21 | OCTOBER 2019 | 1219–1233 | 1219 Articles Nature Cell Biology Ab
    ARTICLES https://doi.org/10.1038/s41556-019-0393-3 Molecular identification of a BAR domain- containing coat complex for endosomal recycling of transmembrane proteins Boris Simonetti1,6, Blessy Paul2,6, Karina Chaudhari3, Saroja Weeratunga2, Florian Steinberg 4, Madhavi Gorla3, Kate J. Heesom5, Greg J. Bashaw3, Brett M. Collins 2,7* and Peter J. Cullen 1,7* Protein trafficking requires coat complexes that couple recognition of sorting motifs in transmembrane cargoes with bio- genesis of transport carriers. The mechanisms of cargo transport through the endosomal network are poorly understood. Here, we identify a sorting motif for endosomal recycling of cargoes, including the cation-independent mannose-6-phosphate receptor and semaphorin 4C, by the membrane tubulating BAR domain-containing sorting nexins SNX5 and SNX6. Crystal structures establish that this motif folds into a β-hairpin, which binds a site in the SNX5/SNX6 phox homology domains. Over sixty cargoes share this motif and require SNX5/SNX6 for their recycling. These include cargoes involved in neuronal migration and a Drosophila snx6 mutant displays defects in axonal guidance. These studies identify a sorting motif and pro- vide molecular insight into an evolutionary conserved coat complex, the ‘Endosomal SNX–BAR sorting complex for promoting exit 1’ (ESCPE-1), which couples sorting motif recognition to the BAR-domain-mediated biogenesis of cargo-enriched tubulo- vesicular transport carriers. housands of transmembrane cargo proteins routinely enter into an endosomal coat complex that couples sequence-dependent the endosomal network where they transit between two fates: cargo recognition with the BAR domain-mediated biogenesis of Tretention within the network for degradation in the lysosome tubulo-vesicular transport carriers.
    [Show full text]
  • Journal Pre-Proof
    Journal Pre-proof A novel homozygous missense variant in MATN3 causes spondylo-epimetaphyseal dysplasia Matrilin 3 type in a consanguineous family Samina Yasin, Saima Mustafa, Arzoo Ayesha, Muhammad Latif, Mubashir Hassan, Muhammad Faisal, Outi Makitie, Furhan Iqbal, Sadaf Naz PII: S1769-7212(20)30038-0 DOI: https://doi.org/10.1016/j.ejmg.2020.103958 Reference: EJMG 103958 To appear in: European Journal of Medical Genetics Received Date: 22 January 2020 Revised Date: 11 May 2020 Accepted Date: 17 May 2020 Please cite this article as: S. Yasin, S. Mustafa, A. Ayesha, M. Latif, M. Hassan, M. Faisal, O. Makitie, F. Iqbal, S. Naz, A novel homozygous missense variant in MATN3 causes spondylo-epimetaphyseal dysplasia Matrilin 3 type in a consanguineous family, European Journal of Medical Genetics (2020), doi: https://doi.org/10.1016/j.ejmg.2020.103958. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2020 Published by Elsevier Masson SAS. Authorship statement Samina Yasin: Methodology, Investigation, Formal analysis, Data curation,
    [Show full text]
  • The Effects of the Female Reproductive Hormones on Ovarian Cancer Initiation and Progression in a Transgenic Mouse Model of the Disease
    THE EFFECTS OF THE FEMALE REPRODUCTIVE HORMONES ON OVARIAN CANCER INITIATION AND PROGRESSION IN A TRANSGENIC MOUSE MODEL OF THE DISEASE Laura Allison Laviolette Thesis submitted to the Faculty of Graduate and Postdoctoral Studies in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Cellular Molecular Medicine Department of Cellular and Molecular Medicine Faculty of Medicine University of Ottawa April 2011 © Laura Allison Laviolette, Ottawa, Canada, 2011 Authorization It is with the rights granted by the Assignment of Copyright Agreement of The Endocrine Society (Endocrinology. 2010 Mar;151(3):929-38) that the manuscript that constitutes Chapter 2 is reproduced. It is with the rights granted by the Copyright Transfer Agreement of Lippincott Williams & Wilkins (Menopause, accepted for publication in May 2011; Volume 18.5) that the manuscript that comprises Chapter 4 is reproduced. Regardless of the formatting requirements of the journals in which the manuscripts contained herein have been submitted or published, the references for this entire document have been formatted into a single list and Canadian English spelling has been used throughout the thesis. ii Contributions of Co-authors All of the studies contained in this thesis were conducted under the supervision of Dr. Barbara Vanderhyden. Unless otherwise specified, all of the experiments were performed by Laura Laviolette. Laura Laviolette designed the experiments, interpreted and analysed the data and wrote the manuscripts, with supervision and revisions from Dr. Barbara Vanderhyden. Chapter 2 Title: 17β-estradiol accelerates tumour onset and decreases survival in a transgenic mouse model of ovarian cancer Journal: Endocrinology (2010 Mar;151(3):929-38) Authors: Laura A.
    [Show full text]
  • Supplementary Table 1 Double Treatment Vs Single Treatment
    Supplementary table 1 Double treatment vs single treatment Probe ID Symbol Gene name P value Fold change TC0500007292.hg.1 NIM1K NIM1 serine/threonine protein kinase 1.05E-04 5.02 HTA2-neg-47424007_st NA NA 3.44E-03 4.11 HTA2-pos-3475282_st NA NA 3.30E-03 3.24 TC0X00007013.hg.1 MPC1L mitochondrial pyruvate carrier 1-like 5.22E-03 3.21 TC0200010447.hg.1 CASP8 caspase 8, apoptosis-related cysteine peptidase 3.54E-03 2.46 TC0400008390.hg.1 LRIT3 leucine-rich repeat, immunoglobulin-like and transmembrane domains 3 1.86E-03 2.41 TC1700011905.hg.1 DNAH17 dynein, axonemal, heavy chain 17 1.81E-04 2.40 TC0600012064.hg.1 GCM1 glial cells missing homolog 1 (Drosophila) 2.81E-03 2.39 TC0100015789.hg.1 POGZ Transcript Identified by AceView, Entrez Gene ID(s) 23126 3.64E-04 2.38 TC1300010039.hg.1 NEK5 NIMA-related kinase 5 3.39E-03 2.36 TC0900008222.hg.1 STX17 syntaxin 17 1.08E-03 2.29 TC1700012355.hg.1 KRBA2 KRAB-A domain containing 2 5.98E-03 2.28 HTA2-neg-47424044_st NA NA 5.94E-03 2.24 HTA2-neg-47424360_st NA NA 2.12E-03 2.22 TC0800010802.hg.1 C8orf89 chromosome 8 open reading frame 89 6.51E-04 2.20 TC1500010745.hg.1 POLR2M polymerase (RNA) II (DNA directed) polypeptide M 5.19E-03 2.20 TC1500007409.hg.1 GCNT3 glucosaminyl (N-acetyl) transferase 3, mucin type 6.48E-03 2.17 TC2200007132.hg.1 RFPL3 ret finger protein-like 3 5.91E-05 2.17 HTA2-neg-47424024_st NA NA 2.45E-03 2.16 TC0200010474.hg.1 KIAA2012 KIAA2012 5.20E-03 2.16 TC1100007216.hg.1 PRRG4 proline rich Gla (G-carboxyglutamic acid) 4 (transmembrane) 7.43E-03 2.15 TC0400012977.hg.1 SH3D19
    [Show full text]
  • Whole Genome Sequencing of Familial Non-Medullary Thyroid Cancer Identifies Germline Alterations in MAPK/ERK and PI3K/AKT Signaling Pathways
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 13 October 2019 doi:10.20944/preprints201910.0154.v1 Article Whole genome sequencing of familial non-medullary thyroid cancer identifies germline alterations in MAPK/ERK and PI3K/AKT signaling pathways Aayushi Srivastava 1,2,3,4, Abhishek Kumar 1,5,6, Sara Giangiobbe 1, Elena Bonora 7, Kari Hemminki 1, Asta Försti 1,2,3 and Obul Reddy Bandapalli 1,2,3,* 1 Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), D-69120, Heidelberg, Germany; [email protected] (A.S.), [email protected] (A.K.); [email protected] (S.G.); [email protected] (K.H.); [email protected] (A.F.) 2 Hopp Children’s Cancer Center (KiTZ), D-69120, Heidelberg, Germany 3 Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), D-69120, Heidelberg, Germany 4 Medical Faculty, Heidelberg University, D-69120, Heidelberg, Germany 5 Institute of Bioinformatics, International Technology Park, Bangalore, 560066, India 6 Manipal Academy of Higher Education (MAHE), Manipal, Karnataka, 576104, India 7 S.Orsola-Malphigi Hospital, Unit of Medical Genetics,40138, Bologna, Italy ; [email protected] * Correspondence: [email protected]; Tel.: +49-6221-42-1709 Abstract: Evidence of familial inheritance in non-medullary thyroid cancer (NMTC) has accumulated over the last few decades. However, known variants account for a very small percentage of the genetic burden. Here, we focused on the identification of common pathways and networks enriched in NMTC families to better understand its pathogenesis with the final aim of identifying one novel high/moderate-penetrance germline predisposition variant segregating with the disease in each studied family.
    [Show full text]
  • Peripheral Nerve Single-Cell Analysis Identifies Mesenchymal Ligands That Promote Axonal Growth
    Research Article: New Research Development Peripheral Nerve Single-Cell Analysis Identifies Mesenchymal Ligands that Promote Axonal Growth Jeremy S. Toma,1 Konstantina Karamboulas,1,ª Matthew J. Carr,1,2,ª Adelaida Kolaj,1,3 Scott A. Yuzwa,1 Neemat Mahmud,1,3 Mekayla A. Storer,1 David R. Kaplan,1,2,4 and Freda D. Miller1,2,3,4 https://doi.org/10.1523/ENEURO.0066-20.2020 1Program in Neurosciences and Mental Health, Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada, 2Institute of Medical Sciences University of Toronto, Toronto, Ontario M5G 1A8, Canada, 3Department of Physiology, University of Toronto, Toronto, Ontario M5G 1A8, Canada, and 4Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5G 1A8, Canada Abstract Peripheral nerves provide a supportive growth environment for developing and regenerating axons and are es- sential for maintenance and repair of many non-neural tissues. This capacity has largely been ascribed to paracrine factors secreted by nerve-resident Schwann cells. Here, we used single-cell transcriptional profiling to identify ligands made by different injured rodent nerve cell types and have combined this with cell-surface mass spectrometry to computationally model potential paracrine interactions with peripheral neurons. These analyses show that peripheral nerves make many ligands predicted to act on peripheral and CNS neurons, in- cluding known and previously uncharacterized ligands. While Schwann cells are an important ligand source within injured nerves, more than half of the predicted ligands are made by nerve-resident mesenchymal cells, including the endoneurial cells most closely associated with peripheral axons. At least three of these mesen- chymal ligands, ANGPT1, CCL11, and VEGFC, promote growth when locally applied on sympathetic axons.
    [Show full text]
  • Loss of Delta Catenin Function in Severe Autism
    Loss of delta catenin function in severe autism The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Turner, T. N., K. Sharma, E. C. Oh, Y. P. Liu, R. L. Collins, M. X. Sosa, D. R. Auer, et al. 2015. “Loss of delta catenin function in severe autism.” Nature 520 (7545): 51-56. doi:10.1038/nature14186. http:// dx.doi.org/10.1038/nature14186. Published Version doi:10.1038/nature14186 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:23473930 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA HHS Public Access Author manuscript Author Manuscript Author ManuscriptNature. Author ManuscriptAuthor manuscript; Author Manuscript available in PMC 2015 October 02. Published in final edited form as: Nature. 2015 April 2; 520(7545): 51–56. doi:10.1038/nature14186. Loss of delta catenin function in severe autism Tychele N. Turner1,2,3, Kamal Sharma4, Edwin C. Oh5, Yangfan P. Liu5, Ryan L. Collins6, Maria X. Sosa1,3, Dallas R. Auer1,3, Harrison Brand6,7, Stephan J. Sanders3,8, Daniel Moreno-De-Luca3,9, Vasyl Pihur1,3, Teri Plona10, Kristen Pike10, Daniel R. Soppet10, Michael W. Smith11, Sau Wai Cheung12, Christa Lese Martin3,13, Matthew W. State3,8, Michael E. Talkowski6,7, Edwin Cook14, Richard Huganir4, Nicholas Katsanis5, and Aravinda Chakravarti1,3 1Center for Complex Disease Genomics, Johns Hopkins University School of Medicine, Baltimore, MD, 21205 USA 2Predoctoral Training Program in Human Genetics and Molecular Biology, McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 21205 USA 3National Institute of Mental Health (NIMH) Autism Centers of Excellence (ACE) Genetics Consortium 4Solomon H.
    [Show full text]